Chrysos Corporation (ASX:C79): The Factors Putting This Stock in Focus

Sonal Goyal

24 September 2026 10:00 PM AEST

Chrysos Corporation (ASX:C79): The Factors Putting This Stock in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• FY26 Revenue of $88.1 million, up 33% on FY25, with EBITDA of $27.2 million up 68% and EBITDA Margin improving to 31% from 24%.

• Record 11.3 million samples processed in FY26 (up 67%), with 1 million samples per month achieved for five consecutive months since March 2026.

• 87 contracted units total (24 new Lease agreements in FY26 plus four post-period), with seven units deployed in FY26 and six currently deploying.

• First-ever operating cashflow positive year with $17.9 million net inflows; $25.9 million cash and $140 million undrawn debt.

Chrysos Corporation (ASX:C79) is the developer and operator of PhotonAssay, a revolutionary gold and multi-element analysis technology that uses high-energy X-rays to provide faster, safer, and more accurate assay results than traditional fire assay methods. The company earns recurring lease revenue from deploying PhotonAssay units to Mining laboratories and directly to mine sites globally. Chrysos operates a capital-light, asset-light model for clients — the company owns the units and receives per-sample or monthly lease income — making its revenue model highly scalable as the unit fleet grows.

Recent Development

Released on 11 August 2026, Chrysos reported FY26 total revenue of $88.1 million (up 33% on FY25's $66.1 million), EBITDA of $27.2 million (up 68% on $16.1 million in FY25), and an improved EBITDA margin of 31% (vs 24% in FY25). The Business became operating cashflow positive for the first time in FY26, generating $17.9 million in net operating cash inflows.

Sample volumes reached a record 11.3 million for the year (up 67% on FY25), with 1 million samples per month achieved for five consecutive months since March 2026 — representing a significant step-change in utilisation and adoption. The contracted unit base grew to 87 (24 new agreements in FY26 plus four post-period), with seven units deployed in FY26 and six currently deploying. Key operational milestones included the first unit deployed to South America (Bureau Veritas in Chile), expansion of the BV relationship with a Kalgoorlie unit, the first next-generation "XN" unit deployed to SGS in Perth, and direct-to-mine agreements with major miners including Newmont. Chrysos now has units deployed with all four major global laboratories.

Sector Context

PhotonAssay addresses a genuine pain point in the global mining industry: traditional fire assay is labour-intensive, slow, uses hazardous chemicals, and has accuracy limitations in certain ore types. Chrysos's technology processes samples 10-20 times faster, uses no chemicals, and delivers higher accuracy for gold and multi-element analysis. The global gold assay market processes billions of samples annually, and Chrysos has barely scratched the surface — at 87 contracted units globally, the technology is in early stages of penetrating a large addressable market. The strategic relationships with all four major global laboratories (Bureau Veritas, SGS, ALS, Intertek) are critical distribution channels that are actively Marketing PhotonAssay to their mining clients.

Risks and Uncertainties

Chrysos's growth is capital-intensive — deploying units requires significant upfront Manufacturing and installation cost, with revenue earned over the multi-year lease term. The company has significant undrawn Debt ($140 million) to fund manufacturing acceleration into FY27 and beyond, but this creates Leverage risk if deployment pace slows. Customer concentration risk exists to the extent that a small number of laboratories and miners represent a large proportion of the contracted portfolio. Any reduction in gold mining activity or exploration spend globally would directly reduce the Demand for assay services. The transition to next-generation "XN" units introduces technology iteration risk around customer adoption rates and performance relative to current units.

Catalysts to Watch

The pace of new unit signings beyond the 87 contracted (four signed post-period suggests strong momentum) and the conversion of six currently-deploying units to revenue-generating status are near-term catalysts. Expansion of the Bureau Veritas relationship to Peru and Mexico (two contracts signed post-period) suggests a systematic rollout of the technology across BV's global laboratory network. Any announcement of direct-to-mine agreements with additional major gold producers would validate the technology's move beyond laboratory channels. The FY27 manufacturing acceleration — enabled by $140 million of undrawn debt — and any FY27 guidance on contracted unit targets and sample Volume expectations will be closely watched.

Final Thoughts

Chrysos Corporation (ASX:C79) is demonstrating the classic SaaS-style flywheel of a technology platform achieving critical mass — growing unit deployments drive sample volume records, which attract new clients, which fund manufacturing scale. Becoming operating cashflow positive in FY26 is a watershed milestone, and with 87 contracted units, strong laboratory partnerships, and a large undrawn facility, the path to continued compounding growth looks well-supported.

FAQs

Q: What is PhotonAssay and how does Chrysos make money?

A: PhotonAssay is a technology that uses high-energy X-rays (photons) to analyse gold and other elements in ore samples — faster, safer, and more accurately than traditional fire assay. Chrysos owns the physical units and earns recurring lease revenue from mining laboratories and mine sites that use the technology to process samples. This creates a predictable, recurring revenue model that scales as more units are deployed and utilisation per unit increases.

Q: What does operating cashflow positive mean for Chrysos?

A: FY26 was the first year in which Chrysos generated more cash from its operating activities than it consumed — $17.9 million in net operating cash inflows. This is a significant milestone that demonstrates the underlying business model is generating cash, reducing dependence on external funding for operations. However, Chrysos continues to use capital for manufacturing new units and deploying them to clients (growth capex), which is funded by the $140 million undrawn debt facility.

Q: What is the XN next-generation unit?

A: The XN (next-generation) unit is an updated version of the PhotonAssay technology, with the first unit deployed to SGS in Perth during FY26. The XN represents Chrysos's product development roadmap — improving performance, potentially reducing manufacturing costs, and staying ahead of competitive alternatives. The successful first deployment of the XN unit validates the technology evolution and could accelerate adoption if the performance improvements attract new clients or upsell existing ones.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.